Clearstead Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Clearstead Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.27K	Buy	+371	New	+$2.42K	﹤0.01%	2436
2026 Q1	–	Sell	-23	Closed	-$203	–	2837
2025 Q4	$203	Sell	23 -1,039	-98%	-$5.72K	﹤0.01%	2417
2025 Q3	$5.3K	Buy	1,062 +590	+125%	+$2.73K	﹤0.01%	2138
2025 Q2	$2.23K	Buy	+472	New	+$2.06K	﹤0.01%	2302
2023 Q1	–	Sell	-50	Closed	-$370	–	1436
2022 Q4	$370	Buy	+50	New	+$487	﹤0.01%	1248

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Clearstead Advisors's VNDA Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Vanda Pharmaceuticals (VNDA) in Q2 2026: 371 shares worth $2.27K. The stake represents ﹤0.01% of the portfolio and ranks #2436 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in VNDA as recently as Q4 2025.

Clearstead Advisors first reported a position in VNDA in Q4 2022 and has held it in 5 quarters since. The position peaked at $5.3K in Q3 2025. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

Clearstead Advisors held 371 shares of Vanda Pharmaceuticals worth $2.27K as of Q2 2026.
Vanda Pharmaceuticals was a new Clearstead Advisors position in Q2 2026.
Vanda Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2436 holding.
Clearstead Advisors first reported a position in Vanda Pharmaceuticals in Q4 2022 and has held it in 5 quarters since.
Clearstead Advisors's Vanda Pharmaceuticals position peaked at $5.3K in Q3 2025.
172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.